Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CEROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CERo Therapeutics Holdings, Inc. filings document material-event disclosures for an emerging growth company with common stock symbol CERO and warrant symbol CEROW. The records identify the warrant class as exercisable for a fractional share of common stock and disclose the company’s registered security classes and exchange-status information in the cited reports.
Recent Form 8-K filings focus on convertible promissory-note financings, including note conversion into common stock, beneficial-ownership limits, exemptions from Securities Act registration, and obligations to register resale shares on Form S-1 or Form S-3. The filings also include an exhibit-based poster presentation related to transplantation and cellular therapy meetings.
CERo Therapeutics Holdings, Inc. filed a current report to note that it has prepared a poster presentation for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster is included as Exhibit 99.1 and is described as summary information meant to be read alongside the company’s other SEC filings and public announcements.
The company states that the poster presentation speaks only as of its date and that it expressly disclaims any obligation to update it, even if circumstances change. The filing is administrative in nature and does not include financial results or major corporate transactions.
CERo Therapeutics Holdings, Inc. filed a current report to note that it has prepared a poster presentation for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster is included as Exhibit 99.1 and is described as summary information meant to be read alongside the company’s other SEC filings and public announcements.
The company states that the poster presentation speaks only as of its date and that it expressly disclaims any obligation to update it, even if circumstances change. The filing is administrative in nature and does not include financial results or major corporate transactions.
CERO Therapeutics Holdings, Inc. reported that the Nasdaq Listing and Hearing Review Council has affirmed a prior decision to delist the company’s securities from the Nasdaq Stock Market. The Council’s decision, dated January 29, 2026, upholds a panel ruling following an earlier trading suspension effective October 31, 2025.
This means the company’s common stock and related warrants will no longer trade on Nasdaq, which can affect trading liquidity and market visibility for shareholders. The filing does not describe any alternative listing venue in this excerpt.
CERO Therapeutics Holdings, Inc. reported that the Nasdaq Listing and Hearing Review Council has affirmed a prior decision to delist the company’s securities from the Nasdaq Stock Market. The Council’s decision, dated January 29, 2026, upholds a panel ruling following an earlier trading suspension effective October 31, 2025.
This means the company’s common stock and related warrants will no longer trade on Nasdaq, which can affect trading liquidity and market visibility for shareholders. The filing does not describe any alternative listing venue in this excerpt.
Cero Therapeutics Holdings, Inc. director Rolfe Lindsey reported receiving a stock option award. On January 7, 2026, he was granted a Stock Option (Right to Buy) covering 690,900 shares of common stock. The option has a conversion or exercise price of $0.055 per share, becomes exercisable on January 7, 2026, and carries an expiration date of January 6, 2036. Following this grant, Lindsey beneficially owned 690,900 derivative securities directly.
Cero Therapeutics Holdings, Inc. director Rolfe Lindsey reported receiving a stock option award. On January 7, 2026, he was granted a Stock Option (Right to Buy) covering 690,900 shares of common stock. The option has a conversion or exercise price of $0.055 per share, becomes exercisable on January 7, 2026, and carries an expiration date of January 6, 2036. Following this grant, Lindsey beneficially owned 690,900 derivative securities directly.
Cero Therapeutics Holdings, Inc. reported that director Kathleen LaPorte received a stock option grant. On January 7, 2026, she was awarded a Stock Option (Right to Buy) covering 690,900 shares of common stock with a conversion or exercise price of $0.055 per share. The option is listed as exercisable on January 7, 2026 and expires on January 6, 2036. Following this grant, LaPorte is shown as directly beneficially owning 690,900 derivative securities linked to the company’s common stock.
Cero Therapeutics Holdings, Inc. reported that director Kathleen LaPorte received a stock option grant. On January 7, 2026, she was awarded a Stock Option (Right to Buy) covering 690,900 shares of common stock with a conversion or exercise price of $0.055 per share. The option is listed as exercisable on January 7, 2026 and expires on January 6, 2036. Following this grant, LaPorte is shown as directly beneficially owning 690,900 derivative securities linked to the company’s common stock.
Cero Therapeutics Holdings, Inc. reported that Chief Development Officer Kristen Pierce received a grant of stock options on 01/07/2026. The award covers 1,612,099 stock options, each representing the right to buy one share of common stock at an exercise price of $0.055 per share. Following this grant, Pierce beneficially owns 1,612,099 derivative securities, all held in direct ownership form.
Cero Therapeutics Holdings, Inc. reported that Chief Development Officer Kristen Pierce received a grant of stock options on 01/07/2026. The award covers 1,612,099 stock options, each representing the right to buy one share of common stock at an exercise price of $0.055 per share. Following this grant, Pierce beneficially owns 1,612,099 derivative securities, all held in direct ownership form.
CERO Therapeutics Holdings, Inc. reported that director Shami Patel received a stock option grant. On January 7, 2026, Patel was awarded an option to buy 690,900 shares of CERO common stock at an exercise price of $0.055 per share. The option is first exercisable on January 7, 2026 and expires on January 6, 2036. After this grant, Patel beneficially owns stock options covering 690,900 shares, held as a direct ownership position.
CERO Therapeutics Holdings, Inc. reported that director Shami Patel received a stock option grant. On January 7, 2026, Patel was awarded an option to buy 690,900 shares of CERO common stock at an exercise price of $0.055 per share. The option is first exercisable on January 7, 2026 and expires on January 6, 2036. After this grant, Patel beneficially owns stock options covering 690,900 shares, held as a direct ownership position.
Cero Therapeutics Holdings director reports large stock option award
Brian G. Atwood, a director of Cero Therapeutics Holdings, Inc., reported receiving a stock option covering 1,612,099 shares of the company’s common stock. The option has an exercise price of $0.055 per share, meaning he can buy up to that number of shares at this fixed price.
The option became exercisable on January 7, 2026 and is scheduled to expire on January 6, 2036, giving a 10‑year exercise window. Following this transaction, Atwood beneficially owns 1,612,099 derivative securities in the form of this stock option, which is reported as held directly.
Cero Therapeutics Holdings director reports large stock option award
Brian G. Atwood, a director of Cero Therapeutics Holdings, Inc., reported receiving a stock option covering 1,612,099 shares of the company’s common stock. The option has an exercise price of $0.055 per share, meaning he can buy up to that number of shares at this fixed price.
The option became exercisable on January 7, 2026 and is scheduled to expire on January 6, 2036, giving a 10‑year exercise window. Following this transaction, Atwood beneficially owns 1,612,099 derivative securities in the form of this stock option, which is reported as held directly.
Cero Therapeutics Holdings, Inc. reported that Chairman and CEO Christopher B. Ehrlich received a large stock option grant. On January 7, 2026, he was awarded a stock option to buy 4,530,997 shares of common stock at an exercise price of $0.055 per share. The option is exercisable from January 7, 2026 and expires on January 6, 2036. Following this grant, he beneficially owns 4,530,997 derivative securities, held as a direct ownership position, and there was no cash price paid for the option itself.
Cero Therapeutics Holdings, Inc. reported that Chairman and CEO Christopher B. Ehrlich received a large stock option grant. On January 7, 2026, he was awarded a stock option to buy 4,530,997 shares of common stock at an exercise price of $0.055 per share. The option is exercisable from January 7, 2026 and expires on January 6, 2036. Following this grant, he beneficially owns 4,530,997 derivative securities, held as a direct ownership position, and there was no cash price paid for the option itself.
Cero Therapeutics Holdings, Inc. director Michael Byrnes received a grant of stock options on January 7, 2026. The award covers 690,900 stock options, each giving the right to buy one share of common stock at an exercise price of $0.055 per share. These options are held as direct ownership and are exercisable starting January 7, 2026, with an expiration date of January 6, 2036. The filing reports this derivative award and the resulting beneficial ownership of 690,900 derivative securities after the transaction.
Cero Therapeutics Holdings, Inc. director Michael Byrnes received a grant of stock options on January 7, 2026. The award covers 690,900 stock options, each giving the right to buy one share of common stock at an exercise price of $0.055 per share. These options are held as direct ownership and are exercisable starting January 7, 2026, with an expiration date of January 6, 2036. The filing reports this derivative award and the resulting beneficial ownership of 690,900 derivative securities after the transaction.
Cero Therapeutics Holdings, Inc. granted its Chief Financial Officer, Andrew Kucharchuk, a stock option on January 7, 2026. The option gives the right to buy 1,162,099 shares of common stock at an exercise price of $0.055 per share. The option is listed as exercisable beginning January 7, 2026 and expires on January 6, 2036. Following this grant, Kucharchuk is reported as directly beneficially owning 1,162,099 derivative securities of this type.
Cero Therapeutics Holdings, Inc. granted its Chief Financial Officer, Andrew Kucharchuk, a stock option on January 7, 2026. The option gives the right to buy 1,162,099 shares of common stock at an exercise price of $0.055 per share. The option is listed as exercisable beginning January 7, 2026 and expires on January 6, 2036. Following this grant, Kucharchuk is reported as directly beneficially owning 1,162,099 derivative securities of this type.